BG103143A - Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives - Google Patents

Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives

Info

Publication number
BG103143A
BG103143A BG103143A BG10314399A BG103143A BG 103143 A BG103143 A BG 103143A BG 103143 A BG103143 A BG 103143A BG 10314399 A BG10314399 A BG 10314399A BG 103143 A BG103143 A BG 103143A
Authority
BG
Bulgaria
Prior art keywords
pirimidocontaining
substituted pyrido
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
BG103143A
Other languages
Bulgarian (bg)
English (en)
Inventor
Yuhpyng Chen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103143A publication Critical patent/BG103143A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG103143A 1996-08-06 1999-02-03 Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives BG103143A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06
PCT/IB1997/000918 WO1998005661A1 (en) 1996-08-06 1997-07-23 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Publications (1)

Publication Number Publication Date
BG103143A true BG103143A (en) 1999-09-30

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103143A BG103143A (en) 1996-08-06 1999-02-03 Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives

Country Status (40)

Country Link
US (1) US6492520B1 (cs)
EP (1) EP0920429B1 (cs)
JP (1) JP3345021B2 (cs)
KR (1) KR20000029843A (cs)
CN (1) CN1093130C (cs)
AP (1) AP1096A (cs)
AR (1) AR008829A1 (cs)
AT (1) ATE232863T1 (cs)
AU (1) AU709203B2 (cs)
BG (1) BG103143A (cs)
BR (1) BR9710808A (cs)
CA (1) CA2262692C (cs)
CO (1) CO4900060A1 (cs)
CZ (1) CZ292806B6 (cs)
DE (1) DE69719193T2 (cs)
DK (1) DK0920429T3 (cs)
DZ (1) DZ2289A1 (cs)
EA (1) EA003188B1 (cs)
ES (1) ES2191183T3 (cs)
GT (1) GT199700089A (cs)
HR (1) HRP970432B1 (cs)
ID (1) ID17980A (cs)
IL (1) IL128188A0 (cs)
IS (1) IS4948A (cs)
MA (1) MA24296A1 (cs)
NO (1) NO313293B1 (cs)
NZ (1) NZ333727A (cs)
OA (1) OA10970A (cs)
PA (1) PA8435201A1 (cs)
PE (1) PE97098A1 (cs)
PL (1) PL331602A1 (cs)
SA (1) SA97180334A (cs)
SK (1) SK14099A3 (cs)
TN (1) TNSN97135A1 (cs)
TR (1) TR199900228T2 (cs)
TW (1) TW550265B (cs)
UY (1) UY24655A1 (cs)
WO (1) WO1998005661A1 (cs)
YU (1) YU5399A (cs)
ZA (1) ZA976954B (cs)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE69917296T2 (de) 1998-08-20 2005-05-25 Smithkline Beecham Corp. Neue substituierte triazolverbindungen
TR200102178T2 (tr) 1998-11-12 2002-01-21 Neurocrine Biosciences, Inc. CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
US6514982B1 (en) 1998-11-12 2003-02-04 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
AU2001234180A1 (en) * 2000-02-25 2001-09-03 Japan Tobacco Inc. Benzamide derivative and use thereof
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
HU229471B1 (en) 2000-10-23 2014-01-28 Smithkline Beecham Corp 2,4,8-trisubstituted-8h-pyrido[2,3d]pyrimidine-7-one compounds, for the treatment of diseases mediated by csbp/p38 kinase
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
HUP0402310A2 (hu) 2001-09-26 2005-02-28 Bayer Pharmaceuticals Corporation 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
PL373339A1 (en) * 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004056807A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005020910A2 (en) * 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
CA2562244A1 (en) * 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510980A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
EP1868612A4 (en) * 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
RU2419610C2 (ru) 2005-05-26 2011-05-27 Ньюрон Системз, Инк. Композиции и способы лечения заболевания сетчатки
EP1979348B1 (en) 2005-12-21 2012-01-18 Abbott Laboratories Anti-viral compounds
CN101384592A (zh) * 2005-12-21 2009-03-11 艾博特公司 抗病毒化合物
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
CA2633760A1 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為fgfr抑制劑之雙環雜環
CN106459092B (zh) * 2014-05-15 2019-10-15 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
ES2845205T3 (es) 2014-09-16 2021-07-26 Gilead Sciences Inc Métodos para preparar moduladores de receptores tipo Toll
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターの固体形態
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MX2018002155A (es) 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
CA3012839A1 (en) 2016-02-12 2017-08-17 Astellas Pharma Inc. Tetrahydroisoquinoline derivatives
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3077362A1 (en) * 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CZ287613B6 (en) * 1994-06-16 2001-01-17 Pfizer Pyrazolo- and pyrrolopyridines and pharmaceutical preparations based thereon
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Icカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
AU716993B2 (en) * 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DE69628804T2 (de) * 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
ATE336495T1 (de) 1996-02-07 2006-09-15 Neurocrine Biosciences Inc Pyrazolopyrimidine als crf rezeptor-antagonisten
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
ZA976954B (en) 1999-02-05
CO4900060A1 (es) 2000-03-27
EA199900083A1 (ru) 1999-08-26
MA24296A1 (fr) 1998-04-01
UY24655A1 (es) 2000-09-29
ID17980A (id) 1998-02-12
KR20000029843A (ko) 2000-05-25
AU3356397A (en) 1998-02-25
AU709203B2 (en) 1999-08-26
BR9710808A (pt) 1999-08-17
DE69719193T2 (de) 2003-09-25
IS4948A (is) 1999-01-19
DK0920429T3 (da) 2003-05-12
HRP970432B1 (en) 2002-10-31
GT199700089A (es) 1999-01-26
ATE232863T1 (de) 2003-03-15
YU5399A (sh) 2002-03-18
AP1096A (en) 2002-08-26
PA8435201A1 (es) 1999-12-27
AR008829A1 (es) 2000-02-23
EP0920429A1 (en) 1999-06-09
OA10970A (en) 2001-11-05
JP3345021B2 (ja) 2002-11-18
DZ2289A1 (fr) 2002-12-25
HRP970432A2 (en) 1998-08-31
DE69719193D1 (de) 2003-03-27
NZ333727A (en) 2000-09-29
CN1093130C (zh) 2002-10-23
NO313293B1 (no) 2002-09-09
CZ41199A3 (cs) 2000-01-12
CZ292806B6 (cs) 2003-12-17
CA2262692C (en) 2002-06-11
NO990544D0 (no) 1999-02-05
CN1227552A (zh) 1999-09-01
HK1021734A1 (en) 2000-06-30
PL331602A1 (en) 1999-08-02
TNSN97135A1 (fr) 2005-03-15
JP2000501116A (ja) 2000-02-02
US6492520B1 (en) 2002-12-10
IL128188A0 (en) 1999-11-30
EA003188B1 (ru) 2003-02-27
PE97098A1 (es) 1999-01-12
TR199900228T2 (xx) 1999-03-22
EP0920429B1 (en) 2003-02-19
AP9701052A0 (en) 1997-10-31
ES2191183T3 (es) 2003-09-01
WO1998005661A1 (en) 1998-02-12
CA2262692A1 (en) 1998-02-12
NO990544L (no) 1999-03-31
SA97180334A (ar) 2005-12-03
TW550265B (en) 2003-09-01
SK14099A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
BG103143A (en) Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives
BG103192A (en) Substituted 6,6-hetero-bicyclic derivatives
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
GR3030668T3 (en) Condensed indole derivatives as 5ht 4?-receptor antagonists.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
MY131298A (en) 5-heteroyl indole derivatives
WO1990003375A3 (en) Fluoro substituted benzocycloheptapyridine compounds, compositions and methods of use
AU2514792A (en) 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
CA2286076A1 (en) Use of 5ht3 antagonists for promoting intestinal lavage
FI990134A0 (fi) Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina
ES8507540A1 (es) Un procedimiento para preparar indeno-piridazinonas sustituidas.
EP0267277A4 (en) COMPOSITIONS CONTAINING 1-SUBSTITUTED LACTAMS.
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
AU2654692A (en) Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists
IT1243801B (it) Intermedi per agenti chelanti con simmetria prefissata, e procedimentoper la loro preparazione
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
GR3017885T3 (en) Substituted aminoacid amide derivatives, their preparation and use as fungicide.
BG102213A (en) Endoparasiticidic composition based on didepsipeptides, new didepsipeptides and method for their preparation
MX9603199A (es) Antagonistas de receptores a endotelina.
AU566900B2 (en) 2,3-dihydro-3-oxo-1h-isoindole derivatives
DE69019186D1 (de) N-substituierte-3-(Stickstoff-enthaltende 5-Ring)-Benzensulfonamid-Derivate, Verfahren zu ihrer Herstellung und Herbizid-Zusammensetzungen.
EP0562575A3 (en) N-substituted-3-(substited hydrazino)-benzenesulfonamide derivatives, prepation process thereof, and herbicidal compositions